Acknowledgements
AIRC IG 21744 to MM Project.
Disclosure statement
AMF: consultancy for Janssen, AbbVie, AstraZeneca, BeiGene. PS: board membership for Janssen, AbbVie, AstraZeneca; payment for lectures including service on speaking bureaus from AbbVie. RM: consultancy for AbbVie, AstraZeneca, Janssen. AV: participation in advisory board for AbbVie, Janssen. GR: consultancy for AbbVie, AstraZeneca, BeiGene, Janssen. FRM: consultancy for AbbVie, Janssen, BeiGene, AstraZeneca, Takeda. CV: consultancy fees and participation in advisory board for Janssen. MM: participation in advisory board for Janssen, AbbVie, Roche, Sanofi. AS: consultancy fees and participation in advisory board for Janssen, AbbVie; participation in advisory board for AstraZeneca, Takeda. MV: participation in advisory board for AbbVie, AstraZeneca, BeiGene, Janssen. MM: payment for lectures including service on speaking bureaus from AbbVie, Janssen. AT: payment for lectures including service on speaking bureaus from AbbVie, Janssen, BeiGene; board membership for Janssen, AbbVie, AstraZeneca, BeiGene.